

1

1 **Title: Thyroid Function Analysis in COVID-19: A Retrospective Study from a Single**

2 **Center**

3 **Running Head: Thyroid Analysis in COVID-19 Pneumonia**

4 **Dr. Jahanzeb Malik^{1*}, Dr. Asmara Malik², Dr. Muhammad Javaid¹, Dr. Tayyaba Zahid¹,**

5 **Dr. Uzma Ishaq³, Dr. Muhammad Shoaib⁴**

6 **1 Department of Cardiology, Rawalpindi Institute of Cardiology, Rawal Road, Rawalpindi,**

7 **46000, Pakistan**

8 **2 Department of Public Health, National University of Medical Sciences, Mall road,**

9 **Saddar, Rawalpindi, 46000, Pakistan**

10 **3 Department of Pathology, Foundation University Medical College, Islamabad, 44000,**

11 **Pakistan**

12 **3 Department of Cardiology, Pakistan Institute of Medical Sciences, Islamabad, 44000,**

13 **Pakistan**

14

15 **Corresponding Author/Proofs**

16 **Dr. Jahanzeb Malik, MBBS, FCPS Cardiology, Senior Registrar Cardiology**

17 **Rawalpindi Institute of Cardiology, Rawal Road, Rawalpindi, 46000, Pakistan**

18 **Heartdoc86@gmail.com**

19 **Contact: 00923215668347**

20 **Word count: 2803**

21 **Keywords: COVID-19, Thyroid diseases, Thyroid-Stimulating Hormone, Triiodothyronine**

22 **Conflict of interest: None to declare**

23 **Funding: None**

24 **Abstract**

25 **Background and Objective**

26 Coronavirus disease 2019 (COVID-19) is an on-going epidemic with a multitude of long-ranging
27 effects on the physiological balance of the human body. It can cause several effects on thyroid
28 functions as well. We aimed to assess the lasting sequelae of COVID-19 on thyroid hormone and
29 the clinical course of the disease as a result.

30 **Methods**

31 Out of 76 patients, 48 patients of COVID-19 positive and 28 patients of COVID-19 negative
32 polymerase chain reaction (PCR) were assessed for thyroid functions, IL-6, and Procalcitonin
33 between moderate, severe, and critical pneumonia.

34 **Results**

35 Seventy-five percent of patients with COVID-19 had thyroid abnormalities and higher IL-6
36 levels (76.10 ± 82.35 vs. 6.99 ± 3.99 , 95% CI 52.18-100.01, P-value <0.01). Logistic regression
37 analysis suggested TT3 (P-value 0.01), IL-6 (P-value <0.01), and Procalcitonin (P-value 0.03) as
38 independent risk factors for COVID-19. ROC curve demonstrated IL-6 as the most sensitive
39 marker (P-value <0.01), and TT3, and Procalcitonin as the predictor for COVID-19 disease.

40 **Conclusion**

41 This pilot study from Pakistan demonstrates that changes in serum TSH and TT3 levels may be
42 important manifestations of the courses of COVID-19 pneumonia.

43 **Keywords:** COVID-19, Thyroid diseases, Thyroid-Stimulating Hormone, Triiodothyronine

44

45

46 **Introduction**

47 The on-going pandemic of coronavirus disease 2019 (COVID-19) has been found to have
48 multiple long-ranging effects on the normal physiological balance of the human body. Complex
49 and severe effects on human organ systems are being identified rapidly, including the
50 respiratory, gastric, circulatory, immune, renal, hepatic, cardiac, and hematological systems.
51 Literature on COVID-19 affecting human thyroid function is increasing gradually and the
52 understanding of thyroid dysfunction and its mechanism is growing. The expression of ACE2
53 combined with transmembrane protease serine 2 (TMPRESS2) is the key cellular complex for
54 the virus to infect the human cells and interestingly both expression levels are present in the
55 thyroid gland, even more than the lungs.¹

56 COVID-19 initiates an immune response over-activity leading to release of pro-
57 inflammatory cytokines, particularly interleukin-6 (IL-6), which leads to overt thyroid
58 dysfunction by disruption of desiodases and thyroid transport proteins. Levels of T3 is inversely
59 proportional to IL-6 with a modest decrease of TSH and T4. This abnormality is described as
60 sick euthyroid syndrome.^{2,3} During the course of COVID-19 pneumonia, thyrotoxicosis may be
61 caused secondary to graves thyroiditis or subacute inflammatory thyroiditis. It can be
62 complicated by arrhythmias or thromboembolic episodes. Hence, abnormalities of thyroid
63 dysfunction are important to evaluate in COVID-19.⁴

64 We conducted a retrospective, cross-sectional study of COVID-19 patients in our hospital
65 in Rawalpindi, Pakistan, compared with a matched cohort of non-COVID-19 patients. Our
66 objectives were to determine if COVID-19 caused acute and subacute thyroid abnormalities, as
67 determined by a diagnostic assessment of thyroid function, and whether thyroid dysfunction
68 leads to a more severe clinical course of COVID-19 in a South Asian population.

69 **Materials and Methods**

70 This retrospective study was approved by the ethical committee at our institute following
71 the World Medical Association Declaration of Helsinki. Patients were considered for inclusion
72 with positive high resolution computed tomography (HRCT) for SARS-CoV-2.

73 The medical records of all the patients admitted at our institute from April 2020 to July
74 2020 with pneumonia were retrospectively examined. Patients with a history of thyroid disease,
75 without assessment and follow-up of thyroid function and IL-6/procalcitonin, pregnancy, and
76 mild COVID-19 infections were excluded from the study. A total of 76 patients were enrolled in
77 this study. Forty-eight with COVID-19 and 28 with non-COVID-19 pneumonia fulfilled the
78 criteria for this study. They were included in this study after written informed consent from the
79 patients. Attrition bias was taken into account. All the tests were taken on initial blood sampling
80 (Day 1) before steroid treatment, IL-6 receptor antagonists, and remdesivir and after three
81 months' (Day 90) follow-up so that no confounding factors produced a bias in this study. This
82 group was screened for underlying thyroid disease or any other medical history that can affect
83 thyroid function.

84 All the cases were labeled as moderate, severe, or critical based on the clinical symptoms,
85 laboratory tests, and chest computed tomography (CT) scans. Moderate and severe cases were
86 classified as having pneumonia manifestations seen on imaging, respiratory rate of ≥ 30
87 breaths/min, and oxygen saturation $\leq 90\%$ at rest. Critical cases were labeled as those requiring
88 mechanical ventilation due to respiratory failure, other organ failures that require intensive care
89 unit, and the presence of shock.

90 All patients included in the study had their thyroid functions, including thyroid-
91 stimulating hormone (TSH), total triiodothyronine (TT3), serum total thyroxine (TT4),

92 procalcitonin, and IL-6 levels done via electrochemiluminescent immunoassay (ECLIA) in the
93 Elecsys® 2010 immunoassay system. All the parameters were analyzed and compared between
94 the COVID-19 and the control group.

95 Data were analyzed with the Statistical Package for the Social Sciences (SPSS) version
96 26 (IBM Corp., Armonk, NY). Quantitative data were presented as mean \pm standard deviation
97 (SD) and qualitative data in frequency and percentages. Both groups were compared using the
98 students' t-test and Chi-square when feasible. Stem and leaf plots were calculated to see the
99 distribution of continuous variables. A receiver operating characteristic (ROC) curve was
100 calculated for thyroid function tests and the acute phase reactants to find out sensitivity and
101 specificity of the lab parameters in COVID-19 pneumonia. Confidence interval (CI) were
102 presented for the lab parameters in all groups. A P-value of less than 0.05 was considered
103 significant.

104

105

106

107

108

109

110

111

112 **Results**

113 During the course of our study, a total of 76 patients were enrolled. Forty-eight with confirmed
114 COVID-19 and 28 patients with non-COVID-19 pneumonia with their thyroid profiles done
115 were also included as controls. Patient demographics and characteristics of pneumonia in both
116 the groups were evenly matched. They are differentiated in **Table 1**.

117 **Table 1.** Demographics and severity of pneumonia

Demographics	COVID (n=48)	Non-COVID (n=28)	P-value
Age (Mean ± SD)	51 ± 19.30	64.79 ± 11.44	0.68
Male (%)	31(64.6%)	15(53.6%)	0.34
Severity			
Moderate	22(45.8%)	8(28.6%)	0.13
Severe	9(18.8%)	10(35.7%)	0.09
Critical	17(35.4%)	10(35.7%)	0.97

118
119 Our examination of the thyroid function analysis suggested that 36 (75%) patients with
120 COVID-19 pneumonia had abnormal thyroid functions while 24 (85.7%) patients were detected
121 with non-COVID-19 pneumonia. IL-6 was significantly higher in COVID-19 group as compared
122 with non-COVID-19 group (76.10 ± 82.35 vs. 6.99 ± 3.99 , 95% CI 52.18-100.01, P-value
123 <0.01).

124 At follow-up, there was a downtrend in IL-6 levels in both groups (14.16 ± 16.58 vs. 4.88
 125 ± 2.66 , P-value <0.01). Procalcitonin levels were statistically significant between both the groups
 126 (P-value <0.01). IL-6 was associated with abnormal TSH, TT3, and TT4 levels (P-value <0.01).
 127 **Table 2** differentiates thyroid profile and acute phase reactants in both COVID-19 and non-
 128 COVID-19 group.

129 **Table 2.** Comparison of thyroid functions and acute phase reactants in both groups

Tests	COVID (n=48)		95% CI	Non- COVID (n=28)		95% CI	P-value
	At admission	At Follow- up		At admissio n	At Follow -up		
IL6 (pg/mL)	76.10 ± 82.35	14.16 ± 16.58	52.18- 100.01	6.99 ± 3.99	4.88 ± 2.66	5.44-8.54	<0.01
Procalcitoni n (mcg/L)	0.36 ± 0.52	0.14 ± 0.32	0.21-0.51	0.06 ± 0.12	0.05 ± 0.08	0.01-0.11	<0.01
TSH (mIU/L)	1.48 ± 2.47	1.11 ± 1.15	0.76-2.20	1.73 ± 2.06	1.65 ± 1.73	0.93-2.53	<0.01
TT3 (ng/dL)	74.62 ± 33.71	89.98 ± 35.15	64.83- 84.42	100.21 ± 45.46	101.86 ± 40.90	82.59- 117.84	<0.01

TT4	6.67 ±	6.79 ±	5.87-7.46	6.43 ±	9 ±	5.48-7.38	0.11
(mcg/dL)	2.74	2.37		2.44	2.77		

130

131 Comparison of TSH and TT3 shows significantly lower mean values in severe COVID-
 132 19 infection as compared with critical patients (0.32 ± 0.22 vs. 2.32 ± 3.44 , P-value <0.01)
 133 (67.44 ± 34.51 vs. 77.12 ± 48.22 , P-value <0.01). A comparison of lab parameters among
 134 different classes of pneumonia is shown in **Table 3**.

135 **Table 3.** Comparison of lab parameters between severity of disease. *P-value <0.05

Tests	Moderate		Severe		Critical	
	Covid (n=22)	Non- covid (n=8)	Covid (n=9)	Non- covid (n=10)	Covid (n=17)	Non- covid (n=10)
TSH	1.31 ± 1.87*	1.28 ± 0.93	0.32 ± 0.22	2.34 ± 2.61	2.32 ± 3.44*	1.49 ± 2.14*
Follow-up	1.13 ± 1.01*	1.68 ± 1.09	0.34 ± 0.14	1.27 ± 0.76	1.50 ± 1.44*	2 ± 2.68*
TT3	75.64 ± 17.03*	111 ± 42.93*	67.44 ± 34.51	95.50 ± 51.08*	77.12 ± 48.22*	96.30 ± 44.86*
Follow-up	86.14 ±	117.38 ±	92.44 ±	88.70 ±	93.65 ±	102.60 ±

	17.67*	38.23*	42.68	32.66*	47.66*	49.08*
TT4	6.91 ± 2.61*	7.88 ± 2.16	7.44 ± 1.81*	6 ± 2.40	5.94 ± 3.24*	5.70 ± 2.40*
Follow-up	7.23 ± 2.15*	11.25 ± 2.91	7.44 ± 1.74*	9.60 ± 1.50	5.88 ± 2.73*	6.60 ± 1.71*

136

137 Logistic regression was performed to determine how levels of thyroid functions and
 138 phase reactants affect the risk of COVID-19 pneumonia. The model suggested TT3 (P-value
 139 0.01), IL-6 (P-value <0.01), and Procalcitonin (P-value 0.03) as independent risk factors for
 140 COVID-19. None of the patients received thyroid hormone replacement therapy, and the levels
 141 of all the thyroid hormones returned to normal after recovery.

142 The stem and leaf plot was generated to demonstrate the distribution of the lab
 143 parameters. It is shown in Figure 1. The area under the ROC (AUC) for IL-6 and Procalcitonin
 144 was 0.941 (95% CI 0.89-0.98, P-value <0.01) and 0.745 (95% CI 0.00-0.63, P-value <0.01),
 145 respectively. TT3 was a predictor of COVID-19 pneumonia with AUC 0.283 (95% CI 0.15-0.40,
 146 P-value <0.01). **Figure 1** suggests that thyroid function tests are not good predictors for
 147 progression to severe COVID-19 infection. The ROC curve indicated IL-6 to be inversely
 148 proportional to TT3.

149 **Figure 1. ROC curve for lab parameters**

150 Differentiation of sensitivity and specificity is shown in **Table 4** and Multivariate analysis in
 151 **Table 5.**

152 **Table 4.** Sensitivity and specificity in predicting COVID-19

Test	Area under the curve	Sensitivity	Specificity	P-value
IL6	0.941	0.979	0.357	<0.01
Procalcitonin	0.745	0.667	0.357	<0.01
TSH	0.378	0.438	0.679	0.07
TT3	0.283	0.375	0.786	<0.01
TT4	0.542	0.479	0.393	0.54

153

154

155

156 **Table 5.** Multivariate analysis of lab parameters in moderate, severe, and critical pneumonia

157

Moderate Pneumonia					
Lab Parameters	B	SE	Wald	OR, 95% CI	P-value
IL-6	0.02	.01	3.49	1.67, 10.46-25.00	0.06
TT3	0.00	.00	0.64	0.12, 73.81-96.32	0.42
TT4	-0.24	.12	4.20	23.81, 6.23-8.10	0.04
TSH	0.14	.14	0.91	0.67, 0.69-1.92	0.33
Procalcitonin	2.73	1.73	2.49	0.15, 0.28-0.12	0.11
Severe Pneumonia					
IL-6	0.00	0.00	1.53	0.32, 16.32-	0.21

				48.60	
TT3	0.00	0.00	0.18	0.76, 60.43-103.99	0.66
TT4	-0.01	0.10	0.01	0.35, 5.62-7.75	0.90
TSH	0.06	0.13	0.21	0.41, 0.35-2.40	0.64
Procalcitonin	-0.27	0.68	0.15	0.39, 0.01-0.47	0.69
Critical Pneumonia					
IL-6	-0.02	0.00	7.80	1.83, 59.83-140.15	0.00
TT3	-0.00	0.00	1.01	0.76, 65.60-102.85	0.01
TT4	0.29	0.13	5.29	0.91, 4.70-7.01	0.02
TSH	-0.17	0.12	1.78	0.16, 0.82-3.20	0.18
Procalcitonin	-1.17	0.77	2.26	2.53, 0.23-0.67	0.13

158

159

160

161

162

163

164

165

166 **Discussion**

167 The results of our study showed that TSH was raised in moderately and critically affected
168 patients of COVID-19 as compared to non-COVID-19 patients. Additionally, TT3 levels were
169 raised significantly more at follow-up in COVID-19 patients than non-COVID-19 patients with
170 little to no discernable effect on TT4 levels. Our findings are in contrast to a similar retrospective
171 study from China, which found lower TSH levels in more severely affected patients of COVID-
172 19 and a study from Italy in which COVID-19 patients were found to have thyrotoxicosis after a
173 confirmatory diagnosis of COVID-19.^{5,6} Although all thyroid function tests returned close to
174 baseline at follow-up in both the Chinese and Italian studies, our study sample showed an outlier
175 in having raised TT3 levels across all three levels of severity of COVID-19. This is of great
176 concern, particularly when paired with the lasting damage to cardiac and respiratory systems
177 which has been documented with regards to COVID-19.⁷ Cardiac abnormalities secondary to
178 thyroid abnormalities may worsen when regarded in the context of post-infectious sequelae.

179 The thyroid gland is a major organ in maintaining many long term functions of the body,
180 in particular, cardiovascular, respiratory, and catabolic tasks, which is why many lower-income
181 countries have implemented salt iodination as a way to counter the consequences of iodine-
182 deficient thyroid disorders.^{8,9} As an emerging disease, COVID-19 has taken a devastating toll in
183 lower-middle-income countries, with seemingly no end in sight to the rising death toll which, at
184 the time of this writing, stands to cross more than 1, 000, 000.¹⁰ As the pandemic rages on, more
185 and more insights are emerging into not just the multi-systemic involvement of the virus, but its
186 impact on disrupting the endocrine system-- with more long-term effects-- can also no longer be
187 overlooked, particularly in the context of countries already struggling with prevalent endocrine
188 diseases.²

189 In Pakistan, the prevalence of hyperthyroidism and subclinical hyperthyroidism is 5.1%
190 and 5.8%, respectively, and hypothyroidism is at 4.1%. Even though hyperthyroid conditions are
191 relatively rare in Pakistan.⁴ Our prevalence seems to be well above the prevalence of both
192 disorders in Europe (0.7%) and the United States (0.5%), while in our closest neighbor, India,
193 subclinical and overt hyperthyroidism were present in 1.6% and 1.3%, respectively and
194 hypothyroidism is comparable at 3.4%.^{9,11}

195 Unlike other countries where COVID-19 has decimated population bases, Pakistan seems
196 to have emerged relatively unscathed from the pandemic.¹² However, given the thyroid
197 abnormalities which have emerged in our study sample, it would seem that the long-term effects
198 of COVID-19, particularly with regards to follow-up of critically ill patients, may be overlooked
199 especially for elderly patients, in which the symptoms of excessive TT3 in circulation—body
200 aches, confusion, increased heart rate—may simply be dismissed as recovery from a viral
201 infection. Concurrently, a thyroid storm with raised inflammatory markers also has overlapping
202 signs and symptoms with the cytokine storm characteristic of COVID-19 worsening in critically
203 ill patients.^{8,13,14,15} Indeed, precedent for the effect of a previous coronavirus affecting the thyroid
204 was established by post-mortem studies of thyroid samples from patients infected with SARS
205 during the 2002 outbreak.¹⁶ This immunogenic and hormonal overlap of a novel disease may
206 further complicate the management and recovery of COVID-19, as corticosteroids used in the
207 treatment of severe COVID-19 may inadvertently cause auto-immune damage to the thyroid
208 gland.^{3,16}

209 Our study was limited to a small pool of consenting patients and less duration of follow-
210 up. One other shortcoming was that free T3, free T4, and other pituitary hormones were not
211 assessed at admission and follow-up due to the retrospective nature of the study. Our institute

14

212 being a tertiary care, it received a higher than moderately severe COVID-19 cases. Hence,
213 patients with mild COVID-19 were not assessed for thyroid functions.

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228 **Conclusion**

229 To the best of our knowledge, this is the first study regarding thyroid disease in Pakistan.
230 This retrospective study provides solid evidence of the high risk of altered thyroid function after
231 COVID-19 pneumonia. We believe our study represents an important direction of exploration of
232 the true cost of the disease, where the overt crises of COVID-19 may mask an emerging crisis of
233 long-term endocrine dysfunctions. Clinical vigilance must be practiced by physicians when
234 monitoring for recovery from COVID-19 for signs and symptoms of thyroid hormone
235 disruptions, particularly in patients of South Asian descent. Further prospective studies will
236 clarify the clinical and prognostic relevance of abnormal behavior of the thyroid gland with
237 COVID-19.

238

239

240

241

242

243

244

245

246

247

248

249

250

16

251

252 **Conflict of Interest**

253 None to declare

254 **Source of funding:**

255 None

256 **Ethical considerations**

257 All patients were enrolled for this study after an informed written consent. Ethical review board
258 of Foundation University gave approval regarding usage of the patient data (FFH/37/DCA/2020),
259 in accordance with the ethical standards of the Declaration of Helsinki.

260 **Acknowledgement**

261 None

262

263

264

265

266

267

268

269

270

271

272

273

274

275 **References**

- 276 1. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the
277 thyroid gland: an update [published online ahead of print, 2020 Nov 25]. *Rev Endocr Metab*
278 *Disord.* 2020;1-13. doi:10.1007/s11154-020-09615-z
- 279 2. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential
280 vaccines: Lessons learned from SARS and MERS epidemic. *Asian Pac J Allergy Immunol.*
281 2020;38(1):1-9. doi:10.12932/AP-200220-0772
- 282 3. Wang W., Ye Y.X., Yao H. Evaluation and observation of serum thyroid hormone and
283 parathyroid hormone in patients with severe acute respiratory syndrome. *J Chin*
284 *Antituberculous Assoc.* 2003;25:232–234.
- 285 4. Khan A, Khan MMA, Akhtar S. Thyroid Disorders, Etiology and Prevalence. *J of Medical*
286 *Sciences.* 2002; 2(2):89–94. doi: 10.3923/jms.2002.89.94
- 287 5. Chen M, Zhou W, Xu W. Thyroid Function Analysis in 50 Patients with COVID-19: A
288 Retrospective Study. *Thyroid.* 2020 Jul 10. doi: 10.1089/thy.2020.0363. Epub ahead of print.
- 289 6. Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients
290 with COVID-19: the THYRCOV study. *Eur J Endocrinol.* 2020 Oct;183(4):381-387. doi:
291 10.1530/EJE-20-0335. PMID: 32698147.
- 292 7. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and
293 Cardiovascular Disease. *Circulation.* 2020 May 19;141(20):1648-1655. doi:
294 10.1161/CIRCULATIONAHA.120.046941.

- 295 8. Dworakowska D, Grossman AB. Thyroid disease in the time of COVID-19. *Endocrine*.
296 2020;68(3):471-474. doi:10.1007/s12020-020-02364-8
- 297 9. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE.
298 Global epidemiology of hyperthyroidism and hypothyroidism. *Nat Rev Endocrinol*. 2018
299 May;14(5):301-316. doi: 10.1038/nrendo.2018.18.
- 300 10. Noor AU, Maqbool F, Bhatti ZA, Khan AU. Epidemiology of CoViD-19 Pandemic:
301 Recovery and mortality ratio around the globe. *Pak J Med Sci*. 2020;36(COVID19-S4):S79-
302 S84. doi:10.12669/pjms.36.COVID19-S4.2660
- 303 11. Unnikrishnan AG, Menon UV. Thyroid disorders in India: An epidemiological
304 perspective. *Indian J Endocrinol Metab*. 2011;15(Suppl 2):S78-S81. doi:10.4103/2230-
305 8210.83329
- 306 12. Abid K, Bari YA, Younas M, Tahir Javaid S, Imran A. Progress of COVID-19 Epidemic in
307 Pakistan. *Asia Pac J Public Health*. 2020;32(4):154-156. doi:10.1177/1010539520927259
- 308 13. Dasgupta A, Kalhan A, Kalra S. Long term complications and rehabilitation of COVID-19
309 patients. *J Pak Med Assoc*. 2020;70(Suppl 3)(5):S131-S135. doi:10.5455/JPMA.32
- 310 14. Bellastella G, Maiorino MI, Esposito K. Endocrine complications of COVID-19: what
311 happens to the thyroid and adrenal glands?. *J Endocrinol Invest*. 2020;43(8):1169-1170.
312 doi:10.1007/s40618-020-01311-8
- 313 15. Brancatella A, Ricci D, Cappellani D, Viola N, Sgrò D, Santini F, Latrofa F. Is Subacute
314 Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a

- 315 Case Series. J Clin Endocrinol Metab. 2020 Oct 1;105(10):dgaa537. doi:
316 10.1210/clinem/dgaa537.
- 317 16. Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute Thyroiditis After
318 Sars-COV-2 Infection. J Clin Endocrinol Metab. 2020;105(7):dgaa276.
319 doi:10.1210/clinem/dgaa276

